Medical Research Company Announces Alzheimer's Treatment Trial Spotlight
Groundbreaking Alzheimer's Treatment Trial by Longeveron to Be Spotlighted at AAIC 2024.
In an unprecedented move that could herald a new era in the battle against Alzheimer's disease, Longeveron Inc., a trailblazer in the field of regenerative medicine, has announced its CLEAR MIND Phase 2a clinical trial focusing on Lomecel-B™ for mild Alzheimer’s Disease will be featured at the 2024 Alzheimer's Association International Conference (AAIC). This pivotal moment is set to shine a spotlight on innovative treatments that promise a brighter future for patients and their families grappling with this devastating condition. $Longeveron(LGVN.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
